# Elevance Health, Inc. (ELV) · Edgar & Edgarette company card

> Elevance Health (ELV) grew revenue 12.5% in FY2025 to $199.1 billion, operating margin 3.6% against a 1.3% median for hospital & medical service plans, equity 36.1% of assets, and dividend per share up 13 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1156039 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/ELV) · [JSON](https://www.pops4.com/boards/company/ELV.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $199.1B |
| Revenue growth, 1 year | 12.5% |
| Revenue growth per year | 9.5% |
| Operating margin | 3.6% (prior year 4.4%) |
| Net margin | 2.8% |
| Operating cash flow | $4.3B |
| Capital spending | $1.1B |
| Free cash flow | $3.2B |
| Cash | $9.5B |
| Long-term debt | $31.9B |
| Total assets | $121.5B |
| Total equity | $43.9B |
| Equity ÷ assets | 36.1% |
| Return on equity | 12.9% |
| Dividend per share | $5.92 |
| Dividend years rising | 13 |

## Readings, computed from those figures

- Piotroski F: 6 of 9 (solid)
- Health Harbor boat: New ship · no warning signs
- Cash Compass: Fast, cash not yet · growing fast, but little cash arriving so far

## Edgarette's reading

Exposure: revenue $199.1B (FY2025), total debt $31.9B. Experience: revenue up 12.5% on the year, up 9.5% a year over 4 years; operating margin 3.6%, down from 4.4%. Soundness: equity 36.1% of assets, return on equity 12.9%, payout 27.0% of profit, dividend per share up 13 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $197.3B and $229.3B next year (method v4.1: its own 4-year record of growth weighed at 50% against $10B+ filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $184.6B to $243.6B. A statistical range, not company guidance. Against peers (10 filers, $50M+ revenue, hospital & medical service plans): operating margin 3.6% against a 1.3% median; growth 12.5% against 12.2%.

Range logged 2026-09-26, receipt 04b80c280be8a801, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-02-26 ([filing](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000019/0001156039-26-000019-index.htm))

## Recent filings

- 10-Q · filed 2026-10-21 · [filing](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000071/0001156039-26-000071-index.htm)
- 8-K · filed 2026-10-21 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000068/0001156039-26-000068-index.htm)
- 8-K · filed 2026-09-10 · 7.01 Regulation FD Disclosure · [filing](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000063/0001156039-26-000063-index.htm)
- 10-Q · filed 2026-07-15 · [filing](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000060/0001156039-26-000060-index.htm)
- 8-K · filed 2026-07-15 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000058/0001156039-26-000058-index.htm)
- 8-K · filed 2026-06-10 · 7.01 Regulation FD Disclosure · [filing](https://www.sec.gov/Archives/edgar/data/1156039/000115603926000049/0001156039-26-000049-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001156039.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1156039

## Cite

POPS4, Edgar & Edgarette: Elevance Health, Inc. (ELV) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/ELV. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.